21 Novembre 2026

Psicologia Punto One | Psicologia e Psicologi nel Web

Menu

Menu

SCHEDA SCIENTIFICA2026Altra ricerca

The molecular and neurochemical basis of altered intrinsic neural timescales in major depressive disorder: a multimodal imaging-transcriptomic investigation of esketamine and sertraline treatment.

Xiang Liu, Yuanzhi He, Lifeng Li, Zhanxiang Hu, Haijun Li, Lihao Wu, Liping Zhang, Zihao Su, HengRui Liu, Guojiang Wu, Dechang Peng

BMC psychiatry · 2026

Abstract originale

INTRODUCTION: Major depressive disorder (MDD) is characterized by dysfunction in higher-order cortical regions involved in emotional and cognitive processes; however, its neurobiological basis remains unclear. Pharmacological treatments, including esketamine and sertraline, produce rapid antidepressant effects. We investigated the local intrinsic neural dynamics underlying these antidepressant effects using intrinsic neural timescales (INT), which measure the duration and capacity of information integration in localized brain regions. METHODS: A total of 57 healthy controls and 41 patients with MDD were included. All patients with MDD received six intravenous infusions of esketamine (0.25 mg/kg) and two weeks of sertraline treatment. All participants underwent resting-state fMRI to quantify INT alterations at the voxel and brain network levels, followed by spatial correlation analyses linking autocorrelation metrics of INT signals to transcriptomic data from the Allen Human Brain Atlas and PET-derived neurotransmitter receptor maps. The spatial correlation between PLS2 scores and case-control t-statistic maps did not pass rigorous spin permutation testing (r = 0.484, p = 0.068) and did not meet the conventional significance threshold of 0.05. Accordingly, all subsequent enrichment analyses based on PLS2 results are presented as exploratory preliminary observations for hypothesis generation. RESULTS: Compared with healthy controls, patients with MDD exhibited significantly elevated INT levels in the left and right precuneus. Following treatment, patients with MDD showed significantly increased INT in the left occipital midline region and left calcarine cortex. At the brain network level, INT levels were significantly reduced in the default mode network (DMN) in patients with MDD compared with healthy controls. Compared with the pre-treatment state, the cerebellar network (CN) showed significantly elevated INT levels after treatment. Partial least squares regression analysis suggested potential associations between INT alterations and spatial gene expression gradients particularly those associated with immune responses, hormonal regulation, neutrophils, regulatory T cells, and glutamatergic synapses. Cell-type enrichment analysis identified excitatory and inhibitory neurons as key cellular contributors. Alterations in INT also correlated with cortical 5-HT1b and NAT receptor density, suggesting a role for inhibitory neurotransmission in temporal integration deficits. CONCLUSION: This study advances understanding of treatment-related brain abnormalities in patients with MDD from the perspective of local neural dynamics. These findings support a multiscale pathophysiological framework involving brain connectivity dynamics, molecular architecture, and neurochemical regulation in MDD.

Parole chiave

HumansMajor Depressive DisorderSertralineFemaleMaleAdultMagnetic Resonance ImagingAntidepressive AgentsKetamineBrainMultimodal ImagingMiddle AgedTranscriptomeCase-Control StudiesEsketamineIntrinsic neural timescaleMajor depressive disorder
Leggi il testo integrale originale

Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.

The molecular and neurochemical basis of altered intrinsic neural timescales in major depressive disorder: a multimodal imaging-transcriptomic investigation of esketamine and sertraline treatment

Introduction

Major depressive disorder (MDD) is characterized by dysfunction in higher-order cortical regions involved in emotional and cognitive processes; however, its neurobiological basis remains unclear. Pharmacological treatments, including esketamine and sertraline, produce rapid antidepressant effects. We investigated the local intrinsic neural dynamics underlying these antidepressant effects using intrinsic neural timescales (INT), which measure the duration and capacity of information integration in localized brain regions.

Methods

A total of 57 healthy controls and 41 patients with MDD were included. All patients with MDD received six intravenous infusions of esketamine (0.25 mg/kg) and two weeks of sertraline treatment. All participants underwent resting-state fMRI to quantify INT alterations at the voxel and brain network levels, followed by spatial correlation analyses linking autocorrelation metrics of INT signals to transcriptomic data from the Allen Human Brain Atlas and PET-derived neurotransmitter receptor maps. The spatial correlation between PLS2 scores and case–control t-statistic maps did not pass rigorous spin permutation testing (r = 0.484, p = 0.068) and did not meet the conventional significance threshold of 0.05. Accordingly, all subsequent enrichment analyses based on PLS2 results are presented as exploratory preliminary observations for hypothesis generation.

Results

Compared with healthy controls, patients with MDD exhibited significantly elevated INT levels in the left and right precuneus. Following treatment, patients with MDD showed significantly increased INT in the left occipital midline region and left calcarine cortex. At the brain network level, INT levels were significantly reduced in the default mode network (DMN) in patients with MDD compared with healthy controls. Compared with the pre-treatment state, the cerebellar network (CN) showed significantly elevated INT levels after treatment. Partial least squares regression analysis suggested potential associations between INT alterations and spatial gene expression gradients particularly those associated with immune responses, hormonal regulation, neutrophils, regulatory T cells, and glutamatergic synapses. Cell-type enrichment analysis identified excitatory and inhibitory neurons as key cellular contributors. Alterations in INT also correlated with cortical 5-HT1b and NAT receptor density, suggesting a role for inhibitory neurotransmission in temporal integration deficits.

Conclusion

This study advances understanding of treatment-related brain abnormalities in patients with MDD from the perspective of local neural dynamics. These findings support a multiscale pathophysiological framework involving brain connectivity dynamics, molecular architecture, and neurochemical regulation in MDD.

Introduction

Major depressive disorder (MDD) is a prevalent mental disorder classified by the World Health Organization as a leading cause of global disability. With a lifetime prevalence of 4.4% in the general population, MDD significantly impairs an individual’s quality of life [1]. The primary clinical features of MDD include persistent low mood, hopelessness, changes in appetite and sleep, fatigue, loss of interest or pleasure in daily activities, and physical symptoms [2]. The diagnosis of MDD primarily relies on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), which requires patients to exhibit five or more symptoms that persist for at least two weeks. Currently, the diagnosis of MDD is largely based on patient symptoms, and clinical manifestations vary substantially among individuals. The heterogeneity of depressive symptoms is associated with multiple factors, including genetics, environment, biology, social psychology, brain anatomy, and alterations in brain function [3].

Current treatments for MDD include medication, psychotherapy, and physical therapy. Medication remains the most common primary treatment strategy [4]. Pharmacological treatments primarily modulate inhibitory neurotransmitters within the central nervous system. Gamma aminobutyric acid (GABA), glutamate (Glu), and monoamine neurotransmitters play crucial pathophysiological roles in mood disorders [5]. In 2019, the U.S. Food and Drug Administration approved esketamine as an antidepressant with a novel mechanism of action [6]. As an N-methyl-d-aspartate receptor antagonist, esketamine rapidly improves mood disturbances and suicidal ideation in patients with MDD by modulating the GABA/glutamatergic system [7]. In recent years, esketamine has been used in adolescent [8]and adult [9]depression populations due to its safety profile and favorable therapeutic outcomes. Sertraline is a selective serotonin reuptake inhibitor (SSRI) that exerts antidepressant effects primarily by regulating monoamine neurotransmitters and has good efficacy and tolerability [10]. Although these two drug classes can improve depressive symptoms and alleviate suicidal ideation in patients with MDD, the neuroanatomical features underlying their therapeutic responses remain unclear. Exploring the neural basis of MDD using neuroimaging techniques can enhance understanding of the potential pathophysiological mechanisms underlying the disorder. This information is crucial for refining diagnostic and treatment strategies.

Functional magnetic resonance imaging (fMRI), which is radiation-free and non-invasive, has advanced the exploration of neural mechanisms in MDD. Common resting-state fMRI techniques include amplitude of low-frequency fluctuation (ALFF) [11], regional homogeneity (ReHo) [12], functional connectivity (FC) [13], and brain network analysis [14]. Lai et al. reported that, compared with the anxiety group, patients with MDD exhibited significantly reduced regional homogeneity in the left cingulate cortex and bilateral anterior cingulate cortex. Changes in ReHo values in the anterior cingulate cortex may represent specific pathophysiological alterations in MDD [15]. An ALFF study confirmed that patients with first-episode adolescent MDD exhibited heightened spontaneous neuronal activity in the medial prefrontal and anterior cingulate cortices, which may explain rumination and impaired attention [16]. A longitudinal independent component analysis study found that a neurodevelopmental model attributed depressive symptoms in adolescent females to abnormalities in functional connectivity patterns among the amygdala, striatum, and prefrontal cortex, which may represent potential targets for early depression detection [17]. These studies have identified regional brain function and network alterations associated with depressive symptoms. Neuroimaging studies examining the relationship between MDD and treatment response have also progressed. One seed-based functional MRI study found that changes in functional connectivity patterns between the cingulate cortex and the whole brain after intravenous ketamine infusion in patients with MDD could predict the antisuicidal effects of ketamine [18]. An FC study found that enhanced FC between the amygdala and medial prefrontal cortex and caudate nucleus may serve as a predictor of the antidepressant effects of ketamine and its efficacy in reducing suicidal ideation [19]. These studies have identified relationships among localized brain function, functional network changes, and antidepressant effects, helping to identify potential therapeutic targets.

The intrinsic neural timescale (INT) improves understanding of local intrinsic brain activity. INT is calculated by assessing the autocorrelation amplitude of resting-state fMRI brain activity to characterize heterogeneity in neural timescales [20]. This measure quantifies intrinsic temporal scales and the time range over which brain regions integrate information [21]. The duration for which neural information is stored across different neural regions is a fundamental functional characteristic of localized brain areas and reflects hierarchical differences between brain structure and neural dynamics [22]. INT is currently used to assess self-awareness and neurodevelopmental status in patients with psychiatric disorders. Watanabe et al. reported that individuals with autism exhibited shorter temporal scales in the sensory/visual cortex and longer temporal scales in the right caudate nucleus, reflecting alterations in higher-order cognitive symptoms in this population [23]. In a study of MDD, reduced intrinsic temporal scales in sensorimotor-, visual-, and cognitive-related regions were associated with disease severity and distinct disease stages [24]. Another study of depression showed that individuals with MDD may exhibit reduced intrinsic temporal scales and spatial disruption in the brain, specifically in the default mode network (DMN) and control networks, offering new insights into the neural basis of depression [25].

Genetic factors play a significant role in brain connectivity, and whole-brain gene expression maps integrate relationships between macroscopic brain networks and microscopic molecular components [26]. The Allen Human Brain Atlas (AHBA) has been used to identify transcriptomes associated with human neuroimaging studies. Integrating multimodal neuroimaging data revealed relationships between the transcriptome and brain function in regions exhibiting neurogenetic vulnerability to MDD [27]. Limited progress has been made in depression research. Li et al. found that gene expression in patients with MDD was correlated with morphologically similar networks, with glial cell- and neuron-specific transcriptional alterations contributing to MDD-specific morphologically similar network associations [28]. Another study found that changes in medial prefrontal cortex thickness in patients with MDD were associated with abnormal functional connectivity patterns. The cortical regions involved in these connectivity patterns showed coupling with AHBA expression, revealing dysregulation of cortical somatostatin-producing interneurons and astrocytes [29].

Based on this, we link the INT associated with MDD to the AHBA to advance our understanding of the relationship between molecular mechanisms and functional alterations in depression. First, we explored MDD-related changes in the intrinsic neural timescale across two independent cohorts. Second, we further investigated the pattern of changes in the intrinsic neural timescale in MDD patients following pharmacotherapy (esketamine combined with sertraline). Finally, we further linked INT abnormalities to anatomical pattern gene expression to explore the relationship between INT and transcriptional patterns, as well as the molecular functions and cell types of INT-associated genes. These observations help us understand how whole-brain gene expression and cell types capture functionally distinct differences in MDD that are molecularly validated.

Materials and methods

Subjects

This was a longitudinal study evaluating the combination of esketamine and sertraline over a 2-week period (Fig. 1). The study enrolled 41 patients with major depressive disorder (MDD) and 57 healthy controls. All MDD patients were enrolled at the Department of Psychosomatic Medicine, The First Affiliated Hospital of Nanchang University between June 2022 and March 2025. MDD patient inclusion criteria: Right-handed, aged 14–65 years, no gender restrictions; meets the diagnostic criteria for a major depressive episode in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); MDD defined as a total score ≥ 24 on the 17-item Hamilton Depression Scale (HAMD-17) with a suicide risk item score ≥ 1; Capable of communicating and providing written informed consent; No abnormal signal foci in brain parenchyma on routine MRI scan. This study was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (Approval No.: IIT2022130). Informed consent was obtained from all participants prior to the study, and they signed informed consent forms.

Exclusion criteria for MDD patients: (1) Exclude patients with other mental disorders, including organic mental disorders, schizophrenia, schizoaffective disorder, bipolar disorder, etc.; (2) Exclude patients who are currently experiencing unstable physical illnesses, such as cardiovascular disease, diabetes, hypertension, hyperthyroidism, hypothyroidism, etc.; (3) Exclude patients with a recent history of alcohol abuse or illicit drug misuse.; (4) Exclude patients with central nervous system disorders, such as neurodegenerative diseases, epilepsy, dementia, or traumatic brain injury.; (5) Exclude patients with organic lesions detected by routine MRI, such as brain tumors or stroke.; (6) Exclude patients with MRI contraindications, such as pacemaker implantation or claustrophobia.; (7) Exclude patients who have previously experienced ineffective results with esketamine or who have contraindications to esketamine administration.; (8) Exclude patients with a history of electroconvulsive therapy or other NMDA receptor antagonist treatment within the past 6 months.

All subjects underwent a rigorous screening process, including clinical evaluation by psychiatrists, review of medical histories, and laboratory testing. During screening, the research team ensured the exclusion of all potential confounding factors that could interfere with the results, thereby guaranteeing the homogeneity of the final enrolled patients and the validity of the data.

Drug use

Esketamine: Indications: This product is indicated for use in combination with an oral antidepressant (sertraline) to alleviate depressive symptoms in patients with major depressive disorder who have acute suicidal ideation or behavior. Dosage Form: Injection; Strength: 50 mg. According to the drug instructions, the dosage is 0.25 mg/kg. After calculating the dosage based on the patient’s weight, prepare esketamine in a 1 g/L solution using normal saline. Administer the solution via intravenous infusion using a microinfusion pump at a rate of 1mL/min. The administration frequency is 3 times per week for 2 consecutive weeks. Esketamine Injection Protocol: (1) Fast for 8 h prior to administration; (2) Monitor temperature, blood pressure, pulse, and respiration hourly before treatment; (3) No food or drink during injection and for 30 min afterward; (4) Family members must remain present throughout the injection and for 30 min afterward to ensure patient safety. Concurrently, the experimental group received conventional oral antidepressant therapy (sertraline) but was prohibited from concomitant use of barbiturates or other anesthetic agents. Sertraline dosage: 50 mg/tablet. Dosage regimen: 50 mg once daily on days 1–4, 100 mg once daily on days 5–8, and 150 mg once daily thereafter.

Clinical scale assessment

Depression and anxiety assessment utilizes the Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) to evaluate patients’ anxiety and depressive symptoms. The HAMA comprises 14 items (somatic anxiety and psychic anxiety), each rated on a 5-point scale from 0 to 4. A total score exceeding 29 indicates possible severe anxiety; over 21 confirms significant anxiety; over 14 confirms anxiety; over 7 indicates possible anxiety; and scores below 6 indicate no anxiety symptoms. The HAMD comprises 17 items [30]. A total score < 7 indicates normal functioning; 7–17 suggests possible depression; 17–24 confirms depression; and > 24 indicates severe depression.

The Montreal Cognitive Assessment (MoCA) evaluates eight cognitive domains: visuospatial processing, executive function, naming, memory, attention, language, abstract reasoning, calculation, and orientation. Patients must be fully conscious and assessed in a quiet environment. The total score ranges from 0 to 30 points, with ≥ 26 indicating normal cognitive function. A score < 26 suggests the presence of cognitive impairment [31].

The Beck Scale for Suicide Ideation (BSI) is used to identify individuals with suicidal tendencies and assess the severity of suicidal thoughts. The scale consists of 19 items, each with three response options (0–2 points), yielding a maximum total score of 38 points. Higher scores indicate greater suicide risk [32].

MRI data acquisition

Imaging data were acquired on a SIEMENS 3.0 T Trio Tim scanner for all patients. All participants completed MRI scans within 24 ± 2 h following their last esketamine infusion. During the examination, subjects were instructed to lie still on the examination table. Earplugs and an eye mask were worn throughout the procedure to minimize external interference. The head was secured with foam padding to prevent movement, and subjects were instructed to breathe through the nose to minimize interference from mouth breathing on head artifacts. Resting-state functional MRI data (BOLD-fMRI) acquisition: Whole-brain BOLD data were acquired using a Gradient-Recalled Echo-Planar Imaging (GRE-EPI) sequence with the following parameters: TR=2000ms; TE=40ms; flip angle=90º; FOV = 230 mm×230 mm; matrix = 64 × 64; 30 consecutive slices; slice thickness = 4.0 mm; slice spacing = 1.2 mm; scan duration = 8 min 06 s.

Data preprocessing

The functional images were preprocessed using the Data Processing Assistant for Resting-State fMRI (DPARSF) [33], implemented on the basis of SPM12 and MATLAB 2022b (MathWorks, Natick, MA, USA). To reduce the influence of unstable magnetization at the beginning of scanning, the initial ten volumes were removed. The remaining images then underwent slice-timing correction and motion realignment to improve temporal alignment across slices. Afterward, the data were normalized to the Montreal Neurological Institute (MNI) standard space and resampled to 3 × 3 × 3 mm3 voxels, followed by detrending and temporal band-pass filtering at 0.01–0.08 Hz. To further control for motion-related effects, volumes with framewise displacement (FD) exceeding 0.2 mm, together with one volume before and two volumes after, were identified and scrubbed, with the affected time points replaced by spline interpolation.

INT estimation

The INT for each voxel across the brain was derived from preprocessed resting-state fMRI data, following the approach of a previous study [23]. The procedure involved: (i) computing the autocorrelation function (ACF) of each voxel’s BOLD signal, using time bins equal to the repetition time (TR); (ii) summing the ACF values over the initial positive period, defined from the first lag up to the point immediately before the ACF became non-positive; and (iii) multiplying this sum by the TR to adjust for temporal resolution. Once voxel-wise INT values were obtained, each subject’s whole-brain INT map was smoothed with a Gaussian kernel (FWHM = 6 mm) to improve the signal-to-noise ratio and subsequently Z-transformed to remove individual differences within groups. The resulting map reflects the temporal integration capacity of local neural dynamics for each brain region.

For further analysis, the fMRI Toolbox (GIFT, version 3.0 b) was used. Twenty-five independent components (ICs) were initially extracted using the minimum description length criterion to account for spatial correlations. Group ICA inverse reconstruction was then applied to obtain ICs for each subject group, and the resulting spatial maps and time courses were converted to z-scores [34]. Components were selected for retention based on their maximum spatial correlation with resting-state network (RSN) templates [35]. Eleven RSNs were ultimately identified. IC selection criteria included: (a) peak activity located predominantly in gray matter, (b) minimal overlap with vascular, ventricular, or other artifacts, and (c) temporal signals dominated by low-frequency activity (power below 0.1 Hz relative to 0.15–0.25 Hz). The RSNs identified included the visual network (VN: IC1, IC3, IC13), executive control network (ECN: IC4, IC18), sensorimotor network (SMN: IC5), default mode network (DMN: IC9, IC16, IC20, IC23), and auditory network (AN: IC22).

Analysis of INT differences between MDD patients and the healthy control group

Generalized linear models (GLMs) were applied to examine between-group regional differences in INT. To better characterize local INT alterations in patients with MDD, cortical areas were further organized based on the Yeo atlas, which defines resting-state functional networks according to cellular structural features. The average INT was then computed for each Yeo-defined network, and case-control differences were evaluated using GLM regression analysis [36]. To control for multiple comparisons across regions, networks, or classes, statistical significance was adjusted using the Benjamini-Hochberg false discovery rate (BH-FDR), with significance set at p < 0.05 of cluster level and p < 0.001 at voxel level.

Calculation of regional gene expression levels

Gene expression profiles were obtained from the Allen Human Brain Atlas (AHBA) using data from six postmortem adult human brains, comprising 3,702 distinct tissue samples [37]. Transcriptomic data were processed and mapped to 90 predefined brain regions with the abagen toolbox [38]. The preprocessing pipeline involved reannotating probes, removing probes with low expression intensity, choosing representative probes, assigning samples to brain regions, imputing missing values, normalizing sample-level data, standardizing gene expression values, averaging samples within each region, and selecting genes with consistently stable expression. After preprocessing, 15,633 genes remained for further study. Since only two of the six donors provided samples from the right hemisphere, subsequent analyses were limited to the left hemisphere. As a result, the final dataset consisted of a gene expression matrix covering 45 brain regions and 15,633 genes.This approach follows common practice in imaging-transcriptomic studies and assumes broad left-right symmetry in normative cortical gene expression, although this assumption cannot fully account for potential hemispheric asymmetry and is therefor acknowledged as a limitation.

Transcription-neuroimaging association analysis

A partial least squares (PLS) regression was performed to examine the association between the expression patterns of 15,633 genes and case-control differences in INT, as indexed by t-values across 45 cortical regions in the left hemisphere [39]. In this model, the predictor matrix consisted of z-score standardized gene expression data (45 regions x 15,633 genes), whereas the response variable was a z-score standardized vector of case-control INT t-values (45 regions x 1). PLS regression extracts latent components representing linear combinations of gene expression variables that maximize the covariance shared with neuroimaging measures. The first latent variable, PLS1, explains the largest proportion of shared covariance, where as subsequent components capture additional, orthogonal gene-neuroimaging covariance patterns.

To determine whether the proportions of variance explained by PLS components were greater than expected by chance, a spatial permutation procedure was applied using a spin test with 10,000 iterations [40]. If none of the PLS components survived spatial permutation correlation, we selected the component with the smallest spatially corrected p value for exploratory downstream analysis, and such results were interpreted as hypothesis-generating rather than confirmatory. In addition, bootstrap resampling was used to estimate the contribution of each gene to the PLS components. Only genes showing significant bootstrap effects after Benjamini-Hochberg false discovery rate correction at p < 0.01 were included in subsequent analyses.

To further explore the link between MDD-related gene expression and INT alterations, MDD-associated genes were obtained from the Allen Human Brain Atlas (AHBA; https://help.brain-map.org/display/humanbrain/Documentation). Genes shared between the MDD-related gene set and the full panel of 15,633 genes were identified. The expression levels of these overlapping genes were then correlated with case-control differences in INT across the left hemisphere. Statistical significance was set at p < 0.05, with false discovery rate correction applied.

Enrichment analysis

To examine the functional relevance of the identified genes, we used Metascape, an automated platform for meta-analysis that helps detect pathways and interaction networks shared across multiple gene sets. Gene sets derived from PLS components in patients with MDD were submitted to Metascape to characterize their biological features and to compare them with genes reported in genome-wide association studies (GWAS). Enrichment analysis was conducted using several annotation resources, including Gene Ontology (GO), Reactome, and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Pathways were considered significant at an FDR-adjusted cutoff of 1%. Because no PLS component survived spatial permutation correction at the conventional p < 0.05 threshold, the component with the smallest spatially corrected p value (PLS2) was used for exploratory enrichment analysis.

Locate MDD-related genes to specific cell types

Postmortem cortical datasets were compiled from seven independent single-cell studies. Using a carefully curated collection of gene sets generated from large-scale single-cell profiling of the adult cerebral cortex by Seidlitz et al. [41], seven principal cell populations were defined, including astrocytes, endothelial cells, microglia, excitatory neurons, inhibitory neurons, oligodendrocytes, and oligodendrocyte precursor cells (OPCs). To evaluate the significance of gene overlap for each cell class, permutation testing was conducted, and only overlaps with FDR-adjusted p-values below 0.05 were regarded as statistically significant. The aim was to determine which cell types were spatially associated with MDD-related INT genes. For subsequent cell-type analyses, PLS2 − was chosen because the genes enriched in this component showed both higher loading scores and larger gene counts than those enriched in PLS2+, suggesting greater exploratory biological relevance.

Associate INT changes with PET neurotransmitter data

To explore the neurochemical mechanisms that may underlie cortical alterations in INT among individuals with MDD, we examined the spatial relationship between regional INT abnormalities and the cortical distribution of neurotransmitter receptors and transporters. For this analysis, we used 39 PET-based maps of receptor and transporter density parcellated according to the AAL90 atlas. These maps were derived from the dataset reported by Hansen et al. (2022) and combine information from multiple tracers and participant subgroups, providing broad coverage of major neuromodulatory systems, including dopaminergic, GABAergic, serotonergic, glutamatergic, and cholinergic pathways [42].

These neurotransmitter systems play essential roles in synaptic signaling, neuronal excitability, and the maintenance of circuit stability, all of which are closely related to the temporal integration processes captured by INT. The PET atlas included receptor and transporter maps for several key targets, such as GABA_A receptors, mGluR5, serotonin receptors 5-HT1a and 5-HT2a, serotonin transporters (5-HTT), dopamine transporters (DAT), and vesicular acetylcholine transporters (VAChT). We then computed the spatial Pearson correlation between the INT alteration map and each receptor/transporter density map. Statistical significance was evaluated using a spin-based permutation test with 10,000 iterations to control for spatial autocorrelation. Multiple-comparison correction was performed using the Benjamini-Hochberg false discovery rate (BH-FDR) procedure.

This multimodal strategy makes it possible to test whether particular neurotransmitter systems, especially those implicated in MDD, contribute to regional susceptibility of INT alterations. In this way, it provides a link between molecular-level neuromodulatory architecture and large-scale temporal dynamics in the human cortex.

Null model construction

To mitigate the potential influence of spatial autocorrelation in neuroimaging and transcriptomic datasets, we applied a spatial permutation approach based on spherical rotations. This “spin test” maintains the intrinsic spatial organization of the brain while breaking the original spatial correspondence between maps through random rotations on the sphere. A total of 10,000 rotations were conducted to construct a null distribution of correlation coefficients, from which spatially corrected p-values (pspin) were obtained. These values were used to determine whether the associations between INT alterations and gene expression patterns derived from PLS analysis, or PET-based neurotransmitter profiles, exceeded what would be expected by chance due to spatial smoothness. By controlling for spatial dependence, this approach helps ensure that the observed associations are more likely to represent meaningful biological links rather than artifacts driven by anatomical proximity, thereby supporting more robust interpretations of the transcriptional and neurochemical basis of INT alterations in depression.

Result

Population, clinical and neurocognitive scales

Summary of demographic and clinical characteristics of the final study participants after exclusion. Table 1 presents the demographic and clinical characteristics of participants. No significant differences were observed between the MDD group and the healthy control group in terms of gender, age, or years of education (41 MDD patients vs. 57 healthy individuals; p > 0.05). MDD patients demonstrated higher scores on the HAMA, HAMD, and suicidal ideation scales compared to healthy individuals, while exhibiting lower MoCA total scores. These differences were statistically significant.

Table 1Demographic and clinical data of HC and MDD before treatment

N HC MDD

(n = 57) (n = 41) t/z P-value

Gender (Male/female) 17/40 10/31 0.103 0.748

Age (year)a 32 ± 11.851 30 ± 11.280 1.063 0.262

Education (year)b 12(9,13) 12(9,12) − 0.277 0.784

HAMAb 3(2,4) 23(20,27.5) -8.459 < 0.001

HAMDb 4(3,5) 36(33,40) -8.463 < 0.001

BSIb 0(0,0) 10(8,10) -8.952 < 0.001

MoCAb 28(27,29) 22(19,24.5) -7.501 < 0.001

MoCA: visual space and execution 5(4,5) 3(2.5,4) -6.276 < 0.001

MoCA: naming 3(3,3) 3(2,3) -2.381 0.026

MoCA: delayed memory 4(4,5) 2(1,3) -6.796 < 0.001

MoCA: attentional function 5(5,6) 5(4,6) -1.439 0.152

MoCA: language 3(3,3) 3(2,3) -3.159 < 0.001

MoCA: abstract 2(2,2) 1(1,2) -4.574 < 0.001

MoCA: orientation 6(6,6) 6(5,6) -3.645 < 0.001

Notes: a Student, t-test; b Wilcoxon-test. n/a indicates that no statistics

Abbreviations: HAMA, Hamilton Anxiety Scale HAMD, Hamilton Depression Scale; BSI, Becker Suicide Ideation Scale༛MoCA, Montreal Cognitive Assessment Scale

Clinical data of MDD patients before and after treatment

Our study found that 41 patients responded well to esketamine treatment. Compared with baseline, HAMA, HAMD, and BSI scores significantly decreased after treatment; MoCA scores significantly increased after treatment (Table 2).

Table 2Demographic and clinical data before and after MDD treatment

MDD(n = 41)

Baseline Post-treatment t/z P-value

HAMAb 23(20,27.5) 8(5.5,12) -5.582 < 0.001

HAMDb 36(33,40) 15(10,19.5) -5.581 < 0.001

BSIb 10(8,10) 2(2,4) -5.624 < 0.001

MoCAb 22(19,24.5) 27(25,28) -5.394 < 0.001

MoCA: visual space and execution 3(2.5,4) 4(3,5) -3.965 < 0.001

MoCA: naming 3(2,3) 3(3,3) -2.887 0.004

MoCA: delayed memory 2(1,3) 4(3,4) -5.130 < 0.001

MoCA: attentional function 5(4,6) 6(4.5,6) -2.394 0.016

MoCA: language 3(2,3) 3(2,3) -3.124 0.001

MoCA: abstract 1(1,2) 2(1,2) -3.153 0.002

MoCA: orientation 6(5,6) 6(6,6) -3.259 < 0.001

Notes: a Student, t-test; b Wilcoxon-test. n/a indicates that no statistics

Abbreviations: HAMA, Hamilton Anxiety Scale HAMD, Hamilton Depression Scale; BSI, Becker Suicide Ideation Scale༛MoCA, Montreal Cognitive Assessment Scale

Voxel-wise analysis of intrinsic neural timescale

Our findings revealed significantly elevated INT in the left and right anterior cingulate cortex of untreated MDD patients compared to the healthy control group at both the voxel-level and cluster-level analysis (GRF-corrected, p < 0.05) (Fig. 2) (Table 3). Additionally, compared with baseline, post-treatment MDD patients exhibited significantly elevated INT in the left occipital midline region and left calcarine cortex (Fig. 2) (Table 4).

Network-level analysis of INT

To further investigate the distribution of INT within large-scale functional systems, we calculated the average voxel INT values across eight representative brain networks: the Auditory Network (AN), Cerebellar Network (CN), Dorsal Attention Network (DAN), Default Mode Network (DMN), Executive Control Network (ECN), Sensorimotor Network (SMN), Salience Network (SN), and Visual Network (VN). We found that untreated MDD patients exhibited significantly reduced DMN INT compared to the healthy control group. Additionally, the CN network showed a significant increase in INT compared to baseline (Fig. 3).

Transcriptomic associations with cortical temporal integration alterations in MDD

We performed partial least squares (PLS) regression to investigate the association between cortical INT alterations in MDD and genome-wide spatial gene expression patterns across the entire cerebral cortex. Before presenting the findings related to PLS2, an important caveat must be highlighted: the spatial spin permutation test examining the correlation between PLS2 scores and case–control t-statistic maps of INT differences did not reach the conventional statistical significance threshold. All subsequent spatial correlation analyses and gene enrichment interpretations derived from PLS2 should therefore be regarded as exploratory preliminary observations intended solely for biological hypothesis generation, and the relevant inferences await replication in independent large-scale cohorts.Although the first PLS component (PLS1) accounted for the largest proportion of gene expression variation, it failed to adequately explain the pathological mechanisms of MDD in subsequent analyses. In contrast, the second PLS component (PLS2) captured a substantial proportion of variance (p < 0.05, corrected) and revealed biologically meaningful correlations. Notably, the spatial distribution of PLS2 scores differed significantly from the spatially constrained null model, indicating a non-random correspondence between gene expression patterns and PD-associated INT alterations (Fig. 4A).Surface projections of PLS2 scores indicate that enriched genes are predominantly distributed in the anterior brain regions, particularly in the left medial prefrontal cortex and the right temporal and insular margins, exhibiting a significant left-sided distribution (Fig. 4B). PLS2 scores exhibited a positive spatial correlation with case–control t-statistic maps reflecting regional INT differences (r = 0.484, p_spin = 0.0684) (Fig. 4C). The spin permutation-derived P value exceeded the conventional threshold of 0.05, indicating that the association failed to pass rigorous significance testing accounting for spatial multiple comparisons. Furthermore, gene loadings ranked by PLS2 revealed distinct gene sets with positive and negative weights (FDR-corrected p < 0.05) (Fig. 4D).

Enrichment analysis

To further elucidate the molecular correlates underlying the INT transcriptomic signature observed in MDD patients, we performed gene set enrichment analysis on positively and negatively weighted genes derived from the PLS2 component. Enriched biological processes for positively loaded genes (PLS2+) were primarily associated with immune responses and hormone regulation. We also found pathways related to neutrophils and regulatory T cells to be overrepresented. Additionally, network visualization highlighted the interconnectedness of metabolic pathways, signaling cascades, and neuroinflammatory processes (Fig. 5A and B). In contrast, negatively weighted genes (PLS2-) showed significant enrichment primarily in signal transduction and protein kinase inhibition. These gene sets included components associated with axons, glutamatergic synapses, and synaptic conformation regulation (Fig. 5C and D).

Transcriptional signatures for canonical brain cell types

To further elucidate the underlying cellular mechanisms of MDD-associated INT alterations,

we mapped disease-related transcriptomic features onto seven representative brain cell types. Spatial projections of cell type-specific expression patterns revealed distinct cortical distributions (Fig. 6A). Enrichment analysis revealed that genes associated with MDD-related changes in INT were significantly enriched in both excitatory (Neuro-Ex) and inhibitory neurons (Neuro-In) (p < 0.05, corrected) (Fig. 6C).

Enrichment heatmap results indicate that distinct cell types exhibit highly specific pathway enrichment patterns. Glial cells show significant enrichment in “axons” and “glutamatergic projections.” In contrast, neuronal subtypes, particularly excitatory (Neuro-Ex) and inhibitory (Neuro-In) neurons, were predominantly enriched in pathways associated with synapses and neuronal function, including “axons”, “regulation of chemical synapse transmission”, “glutamatergic synapses”, and “postsynaptic”. Endothelial cell-associated features were specifically enriched in immune pathways. Astrocytes (Astro), oligodendrocytes (Oligo), and oligodendrocyte precursor cells (OPC) did not show significant pathway enrichment (Fig. 6B). To characterize the functional relationships among these distinct cell types, we constructed a circular graph based on shared Gene Ontology (GO) terms within cell type-specific gene sets. Visualization reveals extensive functional overlap among multiple cell types, with particularly strong interconnections observed between neuronal populations (Neuro-Ex and Neuro-In), as indicated by dense purple bands. Notably, neurons-especially excitatory neurons (Neuro-Ex) exhibit widespread connections with nearly all other cell types (Fig. 6D and E).

Association between INT alterations in PD and neurotransmitter receptor profiles

To assess the contribution of neurotransmitter systems to regional INT alterations in MDD, we evaluated the spatial correlation between regional INT differences and PET-derived density maps across 39 neurotransmitter receptors and transporters. This analysis encompassed a broad range of neuromodulatory systems, including adrenergic transporters, dopaminergic, glutamatergic, GABAergic, serotonergic, and cholinergic systems.

The initial correlations revealed several receptor types that showed nominal associations with the spatial patterns of INT alterations in MDD. However, after correcting spatial autocorrelation using spin tests, only the 5HT1b receptor (r = 0.2223, p = 0.0352, p_spin = 0.0191) and NAT (r = 0.3215, p = 0.002, p_spin = 0.001) remained significantly correlated with cortical INT changes. It is noteworthy that although GABAa receptors showed potential correlations, these associations did not remain statistically significant after spatial correction (Fig. 7).

Table 3Voxel differences between MDD and the healthy control group

Conditions Brain Regions Cluster Sizes (voxels) MNI Coordination t-Score of Peak Voxels

X Y Z

MDD > HC Precuneus_L / R 806 -9 -51 45 14.0493

Abbreviations: MDD, Major depressive disorder; HC, healthy control; MNI, Montreal Neurological Institute

Table 4Voxel differences after MDD treatment

Conditions Brain Regions Cluster Sizes (voxels) MNI Coordination t-Score of Peak Voxels

X Y Z

MDD < MDD treatment Occipital_Mid_L / Calcarine_L 542 0 -87 6 -7.5672

Abbreviations: MDD, Major depressive disorder; HC, healthy control; MNI, Montreal Neurological Institute

Discussion

Our study revealed the following findings. First, voxel-wise analysis demonstrated significantly elevated INT levels in the left and right precuneus of patients with MDD compared with healthy controls (GRF-corrected, p < 0.05). In addition, post-treatment INT levels in the left occipital midline region and left calcarine cortex of patients with MDD were significantly increased relative to baseline. Second, after false discovery rate (FDR) correction at the large-scale network level across eight typical networks, the DMN exhibited a significant reduction in INT between the MDD and HC groups, whereas the CN showed a significant increase in INT after treatment. Third, PLS regression analysis identified PLS2 as the primary component associated with INT alterations. Enrichment analysis of PLS2 + genes revealed key pathways related to the immune response and hormone regulation, neutrophils, and regulatory T cells (r = 0.484, p-spin = 0.0684). PLS2 − genes were associated with signal transduction and protein kinase pathways, including axons, glutamatergic synapses, and regulatory synapses. Fourth, cell-type enrichment analysis revealed that PLS2 was significantly associated with excitatory and inhibitory neurons (FDR < 0.05), indicating that major neuronal types contribute to INT susceptibility. Finally, among the 39 PET-derived neurotransmitter receptor maps, 5-HT1b (r = 0.2223, p = 0.0352) and NAT (r = 0.3215, p = 0.0020) were significantly correlated with changes in INT.

Our results indicate that patients with MDD exhibit significantly elevated INT in both precunei compared with healthy controls. The precuneus is a heterogeneous brain region involved in diverse cognitive functions, including visual processing, mental imagery, and episodic information [43]. Previous studies have linked localized precuneus dysfunction to depression. Zhang et al. found that increased spontaneous neural activity in the precuneus may contribute to cognitive and sensory dysfunction, particularly in the early stages of depression [44]. Abnormal functional connectivity has also been identified between the precuneus and several other brain regions. Fan et al. found that, in patients with MDD and childhood trauma, reduced functional connectivity between the right precuneus and amygdala was significantly associated with diminished physical and social pleasure [45]. Consistent with these studies, we observed significantly elevated INT values in the bilateral precuneus of patients with MDD. This finding indicates prolonged temporal persistence of neural activity and extended information integration within the precuneus, which may contribute to the persistent rumination frequently observed in individuals with depression. The precuneus is a critical node of the DMN [46]. At the large-scale network level, we observed a notable decrease in INT within the DMN of patients with MDD. This result is consistent with previous studies. Zhang et al. found that adolescents with MDD exhibited significantly reduced INT in the DMN across multiple brain regions, including the prefrontal cortex, angular gyrus, middle occipital gyrus, and cerebellum. This reduction in INT within higher-order cortical areas was significantly correlated with disease severity [47]. Reduced DMN integrity indicates that a shortened temporal integration window may lead to inefficient processing of self-related information, potentially explaining the persistence and ineffectiveness of rumination in patients with MDD [48]. We observed globally reduced INT alongside focally elevated INT within the DMN, suggesting heterogeneous temporal abnormalities across discrete DMN subregions rather than uniform global temporal compression. We hypothesize that this network-wide temporal dysregulation may partially account for key clinical phenotypes of MDD, including negative rumination and anhedonia [49].

Compared with pre-treatment levels, INT increased significantly in the left occipital mid-region and left calcarine cortex in patients with MDD after treatment. The left occipital insular region and left calcarine cortex both belong to the primary visual cortex [50]and participate in integrating information into visual working memory [51]. Previous studies of untreated MDD have identified functional alterations in the primary visual cortex [52]. Ketamine treatment may modulate emotional disturbances in MDD by altering neural activity in the occipital lobe. A study of patients with treatment-resistant depression found that ketamine therapy increased glucose metabolism in the bilateral occipital lobes, left hippocampus, and left inferior parietal cortex. These localized metabolic changes were associated with rapid antidepressant effects [53]. Another study found that enhanced functional connectivity between the occipital-parietal and cingulate cortices after ketamine treatment in patients with MDD was associated with rapid antidepressant effects [18]. Consistent with these findings, our results demonstrated altered INT within the primary visual cortex. We speculate that pharmacological treatments may ameliorate impaired visual information processing in patients with MDD. At the brain network level, we did not observe normalization of the DMN; instead, we found increased INT in the CN. Previous studies have provided evidence that ketamine modulates mood disorders by regulating cerebellar function [54]. Loureiro et al. found that ketamine modulated functional connectivity between the cerebellum and large-scale cortical networks, including the frontoparietal and salience networks [55]. Consistent with these findings, we identified prolonged synchronous coupling of intracerebellar neurons. Temporal remodeling within the cerebellar network may partially mediate DMN hypofunction and provides evidence for recovery patterns of temporal integration deficits in MDD. We cannot fully attribute the observed INT alterations to the pharmacological effects of esketamine. Previous functional neuroimaging studies have reported that sertraline alleviates depressive symptoms by modulating brain function. However, robust therapeutic alterations induced by most SSRIs typically require eight weeks or longer to emerge, likely because of their mechanisms of action [56]. In contrast, esketamine exerts rapid antidepressant effects through glutamatergic signaling pathways, as documented in previous investigations. Accordingly, the rapid antidepressant response and concurrent cerebral functional changes observed within the two-week window in the present study are more likely attributable to esketamine administration [57].

Our functional enrichment analysis revealed disease-specific shifts in biological processes associated with gene sets linked to PLS2-mediated INT alterations. This exploratory analysis highlighted functional themes related to immune responses, hormonal regulation, neutrophils, and regulatory T cells. Abnormal immune activation and hormonal dysregulation are key biological mechanisms underlying the onset and progression of depression. Immune activation leads to the release of pro-inflammatory cytokines (IL-1γ, IL-6, tumor necrosis factor) by fibroblasts, endothelial cells, and epithelial cells in the periphery [58]. These cytokines transmit inflammatory signals to the brain through vulnerable regions of the blood-brain barrier, activating the hypothalamic-pituitary-adrenal axis and intensifying the brain’s stress response. Hormonal regulation, particularly through the hypothalamic-pituitary-adrenal axis, releases adrenocorticotropic hormones that regulate the stress hormone cortisol [59]. Elevated cortisol levels suppress receptors in the hippocampus and hypothalamus, leading to functional imbalance in these structures. Persistently high cortisol levels also promote inflammatory responses [60]. Increasing evidence indicates that elevated immune cell levels can induce inflammatory states and thereby contribute to depression progression. Previous studies have shown that peripheral circulating immune cells may induce immune dysfunction by coordinating immune responses and producing cytokines and immunoglobulins [61], involving neutrophils and T cells [62]. Consistent with trends reported in previous studies, our analyses revealed associations between INT metrics and biological processes involving immune responses, hormonal regulatory pathways, and multiple immune cell populations. Based on these observations, we propose the tentative hypothesis that aberrant immune-neuroregulatory crosstalk may partially mediate temporally dysregulated and imbalanced signaling across select cortical regions in depressive states.

In addition, our exploratory analyses revealed associations among INT metrics, signal transduction, and protein kinase pathways within the negative-weighted gene set (PLS2−). These pathways included components related to axonal function, glutamatergic synapses, and synaptic conformation regulation. Previous studies have demonstrated that the glutamatergic system is implicated in the pathophysiology of mood disorders [63]and participates in emotional regulation by modulating the balance between inhibitory and excitatory neurotransmitters. Evidence from post-mortem studies also indicates that emotional disorders are associated with the expression of glutamatergic genes [64], particularly GRIA3, GRIK2, GRIK4, and GRM7 [65]. Consistent with these findings, our results indicate an association between INT metrics and the expression of glutamatergic synapse-related genes. Given that these enrichment signatures lack robust statistical support, we propose a tentative hypothesis requiring further validation: proteins encoded by glutamatergic synaptic genes may participate in synaptic plasticity, which could partially contribute to neuronal integration of synaptic inputs and sustained neural activity [66].

Enrichment analyses derived from PLS2 served as preliminary exploratory evidence in the present study and showed that INT-correlated genes were prominently enriched in patterns linked to excitatory and inhibitory neurons. Excitatory neurons are primarily associated with pathways related to synaptic signaling, axonal development, and neuronal projection targeting and are crucial for maintaining long-distance communication within the brain [67]. Inhibitory neurons are enriched in genes associated with synaptic organization, local inhibition, and circuit regulation and play a crucial role in maintaining cortical computation [68]. The functional balance between excitatory and inhibitory neurons underpins brain function, and its disruption is considered one of the root causes of neurological disorders [69]. Zhu et al. found that, in patients with depression, changes in structural functional connectivity coupling between the default mode network and frontoparietal network are associated with specific gene expression patterns. These enriched genes were primarily related to excitatory neurons, inhibitory neurons, cellular metabolism, and synaptic function [70]. Liu et al. found that, following electroconvulsive therapy in patients with MDD, increased gray matter volume in the motor, prefrontal, and insular cortices was associated with specific functional pathways and cell types; PLS1 was enriched in excitatory and inhibitory neurons [71]. Another study integrated single-cell and bulk-tissue quantitative trait locus data, revealing that disease-causing genes for MDD exhibited specificity across different brain cell types, including excitatory neurons, astrocytes, and oligodendrocytes [70]. Drawing on prior studies and the exploratory molecular imaging coupling signatures observed in the present work, we propose a tentative hypothesis requiring further validation: imbalance between excitatory and inhibitory neurons may correlate with region-specific INT alterations, and such dyshomeostasis could partially mediate impaired information-processing efficiency in patients with MDD.

Additionally, we observed significant spatial correlations between changes in INT and the distribution patterns of PET-derived neurotransmitter receptors, specifically 5-HT1b and NAT receptors. The 5-HT1b receptor may represent a potential therapeutic target for depression [72], as it not only reduces synaptic 5-HT release through negative feedback mechanisms but also modulates the release of other neurotransmitters (acetylcholine, dopamine) [73]. Previous imaging studies have also found that reduced 5-HT1b receptor binding in the raphe nuclei and increased 5-HT1b receptor binding in certain occipital and temporal cortical regions are associated with improved mood [74]. Noradrenergic receptors originate in the locus coeruleus and project to multiple regions of the forebrain. Their functions primarily involve regulating arousal, stress responses, and memory consolidation [75]. Chen et al. found that following treatment with noradrenergic receptor-targeted medications, changes in functional connectivity patterns between the locus coeruleus and the whole brain in patients with major depressive disorder (MDD) corresponded to brain regions where norepinephrine transporters are distributed [76]. Our findings indicate that brain regions with altered INT levels in patients with MDD demonstrate higher densities of 5-HT1b and NAT receptors, suggesting that serotonergic and noradrenergic systems may be linked to temporal integration abnormalities in MDD.

Limitations

Several limitations should be acknowledged. First, all patients with MDD received combined esketamine and sertraline treatment throughout the 2-week intervention, precluding the differentiation of the independent and synergistic effects of the two agents. Second, our imaging-transcriptomic analyses were based on the Allen Human Brain Atlas (AHBA), which provides gene expression data primarily from the left cerebral hemisphere. Because the INT abnormalities identified by resting-state fMRI involved bilateral cortical regions, cross-hemisphere mapping was required. Although this approach is widely adopted and supported by the overall hemispheric symmetry of cortical gene expression, subtle hemisphere-specific expression patterns cannot be excluded and may have affected the robustness of the molecular-imaging associations. Third, the rapid synaptic effects of esketamine are time-dependent, and variability in MRI acquisition intervals may have introduced additional confounding. Finally, the AHBA contains transcriptomic data from healthy donors rather than patients with MDD. Given the widespread transcriptional and epigenetic alterations associated with depression, linking pathological imaging changes to a healthy molecular reference may introduce biological bias. Future studies incorporating depression-specific transcriptomic datasets and independent treatment arms with standardized imaging schedules are warranted to validate and extend these findings.

Conclusion

Our preliminary data indicate that the combination of esketamine and sertraline demonstrates significant antidepressant effects, markedly improving symptoms of MDD. At the voxel level, we found that emotional disturbances and recovery in MDD may be associated with changes in the INT network within specific cortical regions. At the brain network level, MDD patients exhibit alterations in the DMN network’s INT activity. The rapid recovery of emotional disturbances following treatment in MDD patients may be related to compensatory changes in the CN network. Furthermore, transcriptomic analysis revealed distinct molecular signatures underlying INT-associated gene alterations. PLS2 + genes were associated with immune responses, hormonal regulation, and immune cells, while PLS2- genes were linked to signal transduction and protein kinases, and showed significant correlations with excitatory and inhibitory neuronal cell types. Notably, alterations in INT spatially correlate with cortical 5-HT1b receptor and NAT receptor densities, highlighting the critical role of neurotransmitters in regulating temporal integration during MDD. Collectively, these findings underscore the necessity of integrating neurodynamics, gene expression, and receptor localization to enhance our understanding of regional cortical vulnerability in MDD.

References

1.Friedrich MJ Depression Is the Leading Cause of Disability Around the World JAMA 2017 317 15 1517 28418490 10.1001/jama.2017.3826 Friedrich MJ. Depression Is the Leading Cause of Disability Around the World. JAMA. 2017;317(15):1517.10.1001/jama.2017.3826 28418490

2.Tura A Goya-Maldonado R Brain connectivity in major depressive disorder: a precision component of treatment modalities? Transl Psychiatr 2023 13 1 17 10.1038/s41398-023-02499-y PMC10256697 37296121 Tura A, Goya-Maldonado R. Brain connectivity in major depressive disorder: a precision component of treatment modalities? Transl Psychiatr. 2023;13(1):17.10.1038/s41398-023-02499-y PMC10256697 37296121

3.Sequeira SL Butterfield RD Silk JS Forbes EE Ladouceur CD Neural Activation to Parental Praise Interacts With Social Context to Predict Adolescent Depressive Symptoms Front Behav Neurosci 2019 13 15 10.3389/fnbeh.2019.00222 PMC6773803 31607874 Sequeira SL, Butterfield RD, Silk JS, Forbes EE, Ladouceur CD. Neural Activation to Parental Praise Interacts With Social Context to Predict Adolescent Depressive Symptoms. Front Behav Neurosci. 2019;13:15.10.3389/fnbeh.2019.00222 PMC6773803 31607874

4.Standardized treatment strategy for depressive disorder. In: Fang Y, editor. Depressive disorders: mechanisms, measurement and management. Singapore: Springer; 2019;1180:193-199.10.1007/978-981-32-9271-0_10 31784964

5.Koo JW Russo SJ Ferguson D Nestler EJ Duman RS Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior Proc Natl Acad Sci U S A 2010 107 6 2669 74 20133768 PMC2823860 10.1073/pnas.0910658107 Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS. Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U S A. 2010;107(6):2669–74.10.1073/pnas.0910658107 PMC2823860 20133768

6.Kim J Farchione T Potter A Chen Q Temple R Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class N Engl J Med 2019 381 1 1 4 31116916 10.1056/NEJMp1903305 Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class. N Engl J Med. 2019;381(1):1–4.10.1056/NEJMp1903305 31116916

7.Bahji A Vazquez GH Zarate CA Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis J Affect Disord 2021 278 542 55 33022440 10.1016/j.jad.2020.09.071 PMC7704936 Bahji A, Vazquez GH, Zarate CA. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2021;278:542–55.10.1016/j.jad.2020.09.071 PMC7704936 33022440

8.Dwyer JB Landeros-Weisenberger A Johnson JA Tobon AL Flores JM Nasir M Couloures K Sanacora G Bloch MH Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial Am J Psychiat 2021 178 4 352 62 33653121 10.1176/appi.ajp.2020.20010018 Dwyer JB, Landeros-Weisenberger A, Johnson JA, Tobon AL, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. Am J Psychiat. 2021;178(4):352–62.10.1176/appi.ajp.2020.20010018 33653121

9.Ionescu DF Fu DJ Qiu X Lane R Lim P Kasper S Hough D Drevets WC Manji H Canuso CM Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) Int J Neuropsychopharmacol 2021 24 1 22 31 32861217 PMC7816667 10.1093/ijnp/pyaa068 Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, Hough D, Drevets WC, Manji H, Canuso CM. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22–31.10.1093/ijnp/pyaa068 PMC7816667 32861217

10.Yin JT Song XY Wang CY Lin XH Miao MS Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis BMC Psychiatry 2023 23 1 14 10.1186/s12888-023-05382-8 PMC10675869 38001423 Yin JT, Song XY, Wang CY, Lin XH, Miao MS. Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2023;23(1):14.10.1186/s12888-023-05382-8 PMC10675869 38001423

11.Rosenbaum D Int-Veen I Kroczek A Hilsendegen P Velten-Schurian K Bihlmaier I Fallgatter AJ Ehlis AC Amplitude of low frequency fluctuations (ALFF) of spontaneous and induced rumination in major depression: An fNIRS study Sci Rep 2020 10 1 13 10.1038/s41598-020-78317-y PMC7725822 33299001 Rosenbaum D, Int-Veen I, Kroczek A, Hilsendegen P, Velten-Schurian K, Bihlmaier I, Fallgatter AJ, Ehlis AC. Amplitude of low frequency fluctuations (ALFF) of spontaneous and induced rumination in major depression: An fNIRS study. Sci Rep. 2020;10(1):13.10.1038/s41598-020-78317-y PMC7725822 33299001

12.Liu PH Li GZ Zhang AX Yang CX Liu ZF Sun N Zhang KR Brain structural and functional alterations in MDD patient with gastrointestinal symptoms: A resting -state MRI study J Affect Disord 2020 273 95 105 32421626 10.1016/j.jad.2020.03.107 Liu PH, Li GZ, Zhang AX, Yang CX, Liu ZF, Sun N, Zhang KR. Brain structural and functional alterations in MDD patient with gastrointestinal symptoms: A resting -state MRI study. J Affect Disord. 2020;273:95–105.10.1016/j.jad.2020.03.107 32421626

13.Zhang L He CC Liu XY Fan DD Zhang HS Zhang HX Xie CM Thalamic Volumes and Functional Networks Linked With Self-Regulation Dysfunction in Major Depressive Disorder CNS Neurosci Ther 2024 30 11 11 10.1111/cns.70116 PMC11551040 39523461 Zhang L, He CC, Liu XY, Fan DD, Zhang HS, Zhang HX, Xie CM. Thalamic Volumes and Functional Networks Linked With Self-Regulation Dysfunction in Major Depressive Disorder. CNS Neurosci Ther. 2024;30(11):11.10.1111/cns.70116 PMC11551040 39523461

14.Zhang J Cui HJ Yang HD Li YY Xu DD Zhao TY Wu HW Du ZC Huang W Wang C Dynamic changes of large-scale resting-state functional networks in major depressive disorder Prog Neuro-Psychopharmacol Biol Psychiatry 2021 111 9 10.1016/j.pnpbp.2021.110369 34062173 Zhang J, Cui HJ, Yang HD, Li YY, Xu DD, Zhao TY, Wu HW, Du ZC, Huang W, Wang C, et al. Dynamic changes of large-scale resting-state functional networks in major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2021;111:9.10.1016/j.pnpbp.2021.110369 34062173

15.Lai CH The regional homogeneity of cingulate-precuneus regions: The putative biomarker for depression and anxiety J Affect Disord 2018 229 171 6 29316519 10.1016/j.jad.2017.12.086 Lai CH. The regional homogeneity of cingulate-precuneus regions: The putative biomarker for depression and anxiety. J Affect Disord. 2018;229:171–6.10.1016/j.jad.2017.12.086 29316519

16.Zhang XL Cao J Huang Q Hong S Dai LQ Chen XR Chen JM Ai M Gan Y He JL Severity related neuroanatomical and spontaneous functional activity alteration in adolescents with major depressive disorder Front Psychiatry 2023 14 13 10.3389/fpsyt.2023.1157587 PMC10113492 37091700 Zhang XL, Cao J, Huang Q, Hong S, Dai LQ, Chen XR, Chen JM, Ai M, Gan Y, He JL, et al. Severity related neuroanatomical and spontaneous functional activity alteration in adolescents with major depressive disorder. Front Psychiatry. 2023;14:13.10.3389/fpsyt.2023.1157587 PMC10113492 37091700

17.Jin JW Van Snellenberg JX Perlman G DeLorenzo C Klein DN Kotov R Mohanty A Intrinsic neural circuitry of depression in adolescent females J Child Psychol Psychiatry 2020 61 4 480 91 31512744 10.1111/jcpp.13123 PMC7065934 Jin JW, Van Snellenberg JX, Perlman G, DeLorenzo C, Klein DN, Kotov R, Mohanty A. Intrinsic neural circuitry of depression in adolescent females. J Child Psychol Psychiatry. 2020;61(4):480–91.10.1111/jcpp.13123 PMC7065934 31512744

18.Chen XY Zhang B Yuan SQ Luo X Wang MQ Hu YR Zhou YL Ning YP Pre-treatment functional connectivity of the cingulate cortex predicts anti-suicidal effects of serial ketamine infusions Eur Psychiat 2023 66 1 8 10.1192/j.eurpsy.2023.19 PMC10134448 36999368 Chen XY, Zhang B, Yuan SQ, Luo X, Wang MQ, Hu YR, Zhou YL, Ning YP. Pre-treatment functional connectivity of the cingulate cortex predicts anti-suicidal effects of serial ketamine infusions. Eur Psychiat. 2023;66(1):8.10.1192/j.eurpsy.2023.19 PMC10134448 36999368

19.Liu HY Wang CY Lan XF Li WC Zhang F Fu L Ye YX Ning YP Zhou YL Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder Front NeuroSci 2023 17 10 10.3389/fnins.2023.1123797 PMC9932998 36816116 Liu HY, Wang CY, Lan XF, Li WC, Zhang F, Fu L, Ye YX, Ning YP, Zhou YL. Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder. Front NeuroSci. 2023;17:10.10.3389/fnins.2023.1123797 PMC9932998 36816116

20.Golesorkhi M Gomez-Pilar J Zilio F Berberian N Wolff A Yagoub MCE Northoff G The brain and its time: intrinsic neural timescales are key for input processing Commun Biol 2021 4 1 16 10.1038/s42003-021-02483-6 PMC8368044 34400800 Golesorkhi M, Gomez-Pilar J, Zilio F, Berberian N, Wolff A, Yagoub MCE, Northoff G. The brain and its time: intrinsic neural timescales are key for input processing. Commun Biol. 2021;4(1):16.10.1038/s42003-021-02483-6 PMC8368044 34400800

21.Wolff A de la Salle S Sorgini A Lynn E Blier P Knott V Northoff G Atypical Temporal Dynamics of Resting State Shapes Stimulus-Evoked Activity in Depression - An EEG Study on Rest-Stimulus Interaction Front Psychiatry 2019 10 16 10.3389/fpsyt.2019.00719 PMC6803442 31681034 Wolff A, de la Salle S, Sorgini A, Lynn E, Blier P, Knott V, Northoff G. Atypical Temporal Dynamics of Resting State Shapes Stimulus-Evoked Activity in Depression - An EEG Study on Rest-Stimulus Interaction. Front Psychiatry. 2019;10:16.10.3389/fpsyt.2019.00719 PMC6803442 31681034

22.Zhang MZ Niu XY Dang JH Sun JP Wang WJ Cheng JL Zhang Y Analysis of changes in intrinsic neural timescales in male smoking addicts based on whole brain resting-state functional magnetic resonance imaging Zhonghua yi xue za zhi 2024 104 14 1168 73 38583048 10.3760/cma.j.cn112137-20231010-00696 Zhang MZ, Niu XY, Dang JH, Sun JP, Wang WJ, Cheng JL, Zhang Y. Analysis of changes in intrinsic neural timescales in male smoking addicts based on whole brain resting-state functional magnetic resonance imaging. Zhonghua yi xue za zhi. 2024;104(14):1168–73.10.3760/cma.j.cn112137-20231010-00696 38583048

23.Watanabe T Rees G Masuda N Atypical intrinsic neural timescale in autism eLife 2019 8 18 10.7554/eLife.42256 PMC6363380 30717827 Watanabe T, Rees G, Masuda N. Atypical intrinsic neural timescale in autism. eLife. 2019;8:18.10.7554/eLife.42256 PMC6363380 30717827

24.Wei YR Zhang CY Peng YY Chen C Han SQ Wang WJ Zhang Y Lu H Cheng JL MRI Assessment of Intrinsic Neural Timescale and Gray Matter Volume in Parkinson’s Disease J Magn Reson Imaging 2024 59 3 987 95 37318377 10.1002/jmri.28864 Wei YR, Zhang CY, Peng YY, Chen C, Han SQ, Wang WJ, Zhang Y, Lu H, Cheng JL. MRI Assessment of Intrinsic Neural Timescale and Gray Matter Volume in Parkinson’s Disease. J Magn Reson Imaging. 2024;59(3):987–95.10.1002/jmri.28864 37318377

25.Djimbouon F Stoyanov D Çatal Y Paunova R Northoff G Reduced intrinsic neural timescales and their relationship to global network connectivity in depression J Affect Disord 2025 390 9 10.1016/j.jad.2025.119775 40609651 Djimbouon F, Stoyanov D, Çatal Y, Paunova R, Northoff G. Reduced intrinsic neural timescales and their relationship to global network connectivity in depression. J Affect Disord. 2025;390:9.10.1016/j.jad.2025.119775 40609651

26.Hibar DP Stein JL Renteria ME Arias-Vasquez A Desrivières S Jahanshad N Toro R Wittfeld K Abramovic L Andersson M Common genetic variants influence human subcortical brain structures Nature 2015 520 7546 224 U216 10.1038/nature14101 25607358 PMC4393366 Hibar DP, Stein JL, Renteria ME, Arias-Vasquez A, Desrivières S, Jahanshad N, Toro R, Wittfeld K, Abramovic L, Andersson M, et al. Common genetic variants influence human subcortical brain structures. Nature. 2015;520(7546):224–U216.10.1038/nature14101 PMC4393366 25607358

27.Richiardi J Altmann A Milazzo AC Chang C Chakravarty MM Banaschewski T Barker GJ Bokde ALW Bromberg U Büchel C Correlated gene expression supports synchronous activity in brain networks Science 2015 348 6240 1241 4 26068849 PMC4829082 10.1126/science.1255905 Richiardi J, Altmann A, Milazzo AC, Chang C, Chakravarty MM, Banaschewski T, Barker GJ, Bokde ALW, Bromberg U, Büchel C, et al. Correlated gene expression supports synchronous activity in brain networks. Science. 2015;348(6240):1241–4.10.1126/science.1255905 PMC4829082 26068849

28.Li J Seidlitz J Suckling J Fan FY Ji GJ Meng Y Yang SQ Wang K Qiu J Chen HF Cortical structural differences in major depressive disorder correlate with cell type-specific transcriptional signatures Nat Commun 2021 12 1 14 10.1038/s41467-021-21943-5 PMC7955076 33712584 Li J, Seidlitz J, Suckling J, Fan FY, Ji GJ, Meng Y, Yang SQ, Wang K, Qiu J, Chen HF, et al. Cortical structural differences in major depressive disorder correlate with cell type-specific transcriptional signatures. Nat Commun. 2021;12(1):14.10.1038/s41467-021-21943-5 PMC7955076 33712584

29.Anderson KM Collins MA Kong R Fang K Li JW He T Chekroud AM Yeo BTT Holmes AJ Convergent molecular, cellular, and cortical neuroimaging signatures of major depressive disorder Proc Natl Acad Sci U S A 2020 117 40 25138 49 32958675 PMC7547155 10.1073/pnas.2008004117 Anderson KM, Collins MA, Kong R, Fang K, Li JW, He T, Chekroud AM, Yeo BTT, Holmes AJ. Convergent molecular, cellular, and cortical neuroimaging signatures of major depressive disorder. Proc Natl Acad Sci U S A. 2020;117(40):25138–49.10.1073/pnas.2008004117 PMC7547155 32958675

30.Hamilton M A rating scale for depression J Neurol Neurosurg Psychiatry 1960 23 56 62 14399272 PMC495331 10.1136/jnnp.23.1.56 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.10.1136/jnnp.23.1.56 PMC495331 14399272

31.Nasreddine ZS Phillips NA Bédirian V Charbonneau S Whitehead V Collin I Cummings JL Chertkow H The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment J Am Geriatr Soc 2005 53 4 695 9 15817019 10.1111/j.1532-5415.2005.53221.x Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.10.1111/j.1532-5415.2005.53221.x 15817019

32.Beck AT Kovacs M Weissman A Assessment of suicidal intention: the Scale for Suicide Ideation J Consult Clin Psychol 1979 47 2 343 52 469082 10.1037/0022-006X.47.2.343 Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979;47(2):343–52.10.1037//0022-006x.47.2.343 469082

33.Yan CG Wang XD Zuo XN Zang YF DPABI: Data Processing & Analysis for (Resting-State) Brain Imaging Neuroinformatics 2016 14 3 339 51 27075850 10.1007/s12021-016-9299-4 Yan CG, Wang XD, Zuo XN, Zang YF. DPABI: Data Processing & Analysis for (Resting-State) Brain Imaging. Neuroinformatics. 2016;14(3):339–51.10.1007/s12021-016-9299-4 27075850

34.Zuo XN Kelly C Adelstein JS Klein DF Castellanos FX Milham MP Reliable intrinsic connectivity networks: Test-retest evaluation using ICA and dual regression approach NeuroImage 2010 49 3 2163 77 19896537 10.1016/j.neuroimage.2009.10.080 PMC2877508 Zuo XN, Kelly C, Adelstein JS, Klein DF, Castellanos FX, Milham MP. Reliable intrinsic connectivity networks: Test-retest evaluation using ICA and dual regression approach. NeuroImage. 2010;49(3):2163–77.10.1016/j.neuroimage.2009.10.080 PMC2877508 19896537

35.Shirer WR Ryali S Rykhlevskaia E Menon V Greicius MD Decoding Subject-Driven Cognitive States with Whole-Brain Connectivity Patterns Cereb Cortex 2012 22 1 158 65 21616982 10.1093/cercor/bhr099 PMC3236795 Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD. Decoding Subject-Driven Cognitive States with Whole-Brain Connectivity Patterns. Cereb Cortex. 2012;22(1):158–65.10.1093/cercor/bhr099 PMC3236795 21616982

36.Brovelli A Chicharro D Badier JM Wang HF Jirsa V Characterization of Cortical Networks and Corticocortical Functional Connectivity Mediating Arbitrary Visuomotor Mapping J Neurosci 2015 35 37 12643 58 26377456 PMC6795203 10.1523/JNEUROSCI.4892-14.2015 Brovelli A, Chicharro D, Badier JM, Wang HF, Jirsa V. Characterization of Cortical Networks and Corticocortical Functional Connectivity Mediating Arbitrary Visuomotor Mapping. J Neurosci. 2015;35(37):12643–58.10.1523/JNEUROSCI.4892-14.2015 PMC6795203 26377456

37.Hawrylycz MJ Lein ES Guillozet-Bongaarts AL Shen EH Ng L Miller JA van de Lagemaat LN Smith KA Ebbert A Riley ZL An anatomically comprehensive atlas of the adult human brain transcriptome Nature 2012 489 7416 391 9 10.1038/nature11405 22996553 PMC4243026 Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, van de Lagemaat LN, Smith KA, Ebbert A, Riley ZL, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012;489(7416):391–9.10.1038/nature11405 PMC4243026 22996553

38.Markello RD Arnatkeviciute A Poline JB Fulcher B Fornito A Misic B Standardizing workflows in imaging transcriptomics with the abagen toolbox eLife 2021 10 27 10.7554/eLife.72129 PMC8660024 34783653 Markello RD, Arnatkeviciute A, Poline JB, Fulcher B, Fornito A, Misic B. Standardizing workflows in imaging transcriptomics with the abagen toolbox. eLife. 2021;10:27.10.7554/eLife.72129 PMC8660024 34783653

39.Abdi H Williams LJ Partial least squares methods: partial least squares correlation and partial least square regression Methods Mol biology (Clifton NJ) 2013 930 549 79 10.1007/978-1-62703-059-5_23 23086857 Abdi H, Williams LJ. Partial least squares methods: partial least squares correlation and partial least square regression. Methods Mol biology (Clifton NJ). 2013;930:549–79.10.1007/978-1-62703-059-5_23 23086857

40.Alexander-Bloch AF Shou HC Liu SY Satterthwaite TD Glahn DC Shinohara RT Vandekar SN Raznahan A On testing for spatial correspondence between maps of human brain structure and function NeuroImage 2018 178 540 51 29860082 PMC6095687 10.1016/j.neuroimage.2018.05.070 Alexander-Bloch AF, Shou HC, Liu SY, Satterthwaite TD, Glahn DC, Shinohara RT, Vandekar SN, Raznahan A. On testing for spatial correspondence between maps of human brain structure and function. NeuroImage. 2018;178:540–51.10.1016/j.neuroimage.2018.05.070 PMC6095687 29860082

41.Seidlitz J Nadig A Liu SY Bethlehem RAI Vértes PE Morgan SE Vása F Romero-Garcia R Lalonde FM Clasen LS Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disorders Nat Commun 2020 11 1 14 10.1038/s41467-020-17051-5 PMC7335069 32620757 Seidlitz J, Nadig A, Liu SY, Bethlehem RAI, Vértes PE, Morgan SE, Vása F, Romero-Garcia R, Lalonde FM, Clasen LS, et al. Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disorders. Nat Commun. 2020;11(1):14.10.1038/s41467-020-17051-5 PMC7335069 32620757

42.Hansen JY Shafiei G Markello RD Smart K Cox SML Norgaard M Beliveau V Wu YJ Gallezot JD Aumont É Mapping neurotransmitter systems to the structural and functional organization of the human neocortex Nat Neurosci 2022 25 11 1569 10.1038/s41593-022-01186-3 36303070 PMC9630096 Hansen JY, Shafiei G, Markello RD, Smart K, Cox SML, Norgaard M, Beliveau V, Wu YJ, Gallezot JD, Aumont É, et al. Mapping neurotransmitter systems to the structural and functional organization of the human neocortex. Nat Neurosci. 2022;25(11):1569–.10.1038/s41593-022-01186-3 PMC9630096 36303070

43.Dörfel D Werner A Schaefer M von Kummer R Karl A Distinct brain networks in recognition memory share a defined region in the precuneus Eur J Neurosci 2009 30 10 1947 59 19895564 10.1111/j.1460-9568.2009.06973.x Dörfel D, Werner A, Schaefer M, von Kummer R, Karl A. Distinct brain networks in recognition memory share a defined region in the precuneus. Eur J Neurosci. 2009;30(10):1947–59.10.1111/j.1460-9568.2009.06973.x 19895564

44.Zhang B Qi SL Liu S Liu XY Wei XH Ming D Altered spontaneous neural activity in the precuneus, middle and superior frontal gyri, and hippocampus in college students with subclinical depression BMC Psychiatry 2021 21 1 10 10.1186/s12888-021-03292-1 34074266 PMC8167968 Zhang B, Qi SL, Liu S, Liu XY, Wei XH, Ming D. Altered spontaneous neural activity in the precuneus, middle and superior frontal gyri, and hippocampus in college students with subclinical depression. BMC Psychiatry. 2021;21(1):10.10.1186/s12888-021-03292-1 PMC8167968 34074266

45.Fan J Gao F Wang X Liu Q Xia J Han Y Yi JY Tan CL Zhu XZ Right amygdala-right precuneus connectivity is associated with childhood trauma in major depression patients and healthy controls Soc Cogn Affect Neurosci 2023 18 1 8 10.1093/scan/nsac064 PMC10036873 36639930 Fan J, Gao F, Wang X, Liu Q, Xia J, Han Y, Yi JY, Tan CL, Zhu XZ. Right amygdala-right precuneus connectivity is associated with childhood trauma in major depression patients and healthy controls. Soc Cogn Affect Neurosci. 2023;18(1):8.10.1093/scan/nsac064 PMC10036873 36639930

46.Utevsky AV Smith DV Huettel SA Precuneus Is a Functional Core of the Default-Mode Network J Neurosci 2014 34 3 932 40 24431451 PMC3891968 10.1523/JNEUROSCI.4227-13.2014 Utevsky AV, Smith DV, Huettel SA. Precuneus Is a Functional Core of the Default-Mode Network. J Neurosci. 2014;34(3):932–40.10.1523/JNEUROSCI.4227-13.2014 PMC3891968 24431451

47.Zheng RP Bu CX Chen Y Wei YR Zhou BQ Jiang Y Zhu CD Wang KF Wang CH Li SY Decreased intrinsic neural timescale in treatment-naïve adolescent depression J Affect Disord 2024 348 389 97 38160888 10.1016/j.jad.2023.12.048 Zheng RP, Bu CX, Chen Y, Wei YR, Zhou BQ, Jiang Y, Zhu CD, Wang KF, Wang CH, Li SY, et al. Decreased intrinsic neural timescale in treatment-naïve adolescent depression. J Affect Disord. 2024;348:389–97.10.1016/j.jad.2023.12.048 38160888

48.Liang Q Xu Z Chen S Lin S Lin X Li Y Zhang Y Peng B Hou G Qiu Y Temporal dysregulation of the somatomotor network in agitated depression Brain Commun 2024 6 6 fcae425 39659972 PMC11630518 10.1093/braincomms/fcae425 Liang Q, Xu Z, Chen S, Lin S, Lin X, Li Y, Zhang Y, Peng B, Hou G, Qiu Y. Temporal dysregulation of the somatomotor network in agitated depression. Brain Commun. 2024;6(6):fcae425.10.1093/braincomms/fcae425 PMC11630518 39659972

49.Posner J Cha J Wang ZS Talati A Warner V Gerber A Peterson BS Weissman M Increased Default Mode Network Connectivity in Individuals at High Familial Risk for Depression Neuropsychopharmacology 2016 41 7 1759 67 26593265 10.1038/npp.2015.342 PMC4869043 Posner J, Cha J, Wang ZS, Talati A, Warner V, Gerber A, Peterson BS, Weissman M. Increased Default Mode Network Connectivity in Individuals at High Familial Risk for Depression. Neuropsychopharmacology. 2016;41(7):1759–67.10.1038/npp.2015.342 PMC4869043 26593265

50.Liu DY Ju X Gao Y Han JF Li Z Hu XW Tan ZL Northoff G Song XM From Molecular to Behavior: Higher Order Occipital Cortex in Major Depressive Disorder Cereb Cortex 2022 32 10 2129 39 34613359 PMC9113303 10.1093/cercor/bhab343 Liu DY, Ju X, Gao Y, Han JF, Li Z, Hu XW, Tan ZL, Northoff G, Song XM. From Molecular to Behavior: Higher Order Occipital Cortex in Major Depressive Disorder. Cereb Cortex. 2022;32(10):2129–39.10.1093/cercor/bhab343 PMC9113303 34613359

51.Makovski T Lavidor M Stimulating occipital cortex enhances visual working memory consolidation Behav Brain Res 2014 275 84 7 25205369 10.1016/j.bbr.2014.09.004 Makovski T, Lavidor M. Stimulating occipital cortex enhances visual working memory consolidation. Behav Brain Res. 2014;275:84–7.10.1016/j.bbr.2014.09.004 25205369

52.Yan MQ He YQ Cui XL Liu F Li HB Huang RZ Tang YQ Chen JD Zhao JP Xie GR Disrupted Regional Homogeneity in Melancholic and Non-melancholic Major Depressive Disorder at Rest Front Psychiatry 2021 12 13 10.3389/fpsyt.2021.618805 PMC7928375 33679477 Yan MQ, He YQ, Cui XL, Liu F, Li HB, Huang RZ, Tang YQ, Chen JD, Zhao JP, Xie GR, et al. Disrupted Regional Homogeneity in Melancholic and Non-melancholic Major Depressive Disorder at Rest. Front Psychiatry. 2021;12:13.10.3389/fpsyt.2021.618805 PMC7928375 33679477

53.Carlson PJ Diazgranados N Nugent AC Ibrahim L Luckenbaugh DA Brutsche N Herscovitch P Manji HK Zarate CA Drevets WC Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study Biol Psychiatry 2013 73 12 1213 21 23540908 PMC3672258 10.1016/j.biopsych.2013.02.008 Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, Herscovitch P, Manji HK, Zarate CA, Drevets WC. Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study. Biol Psychiatry. 2013;73(12):1213–21.10.1016/j.biopsych.2013.02.008 PMC3672258 23540908

54.Sahib AK Loureiro JR Vasavada M Anderson C Kubicki A Wade B Joshi SH Woods RP Congdon E Espinoza R Modulation of the functional connectome in major depressive disorder by ketamine therapy Psychol Med 2022 52 13 2596 605 33267926 10.1017/S0033291720004560 PMC9647551 Sahib AK, Loureiro JR, Vasavada M, Anderson C, Kubicki A, Wade B, Joshi SH, Woods RP, Congdon E, Espinoza R, et al. Modulation of the functional connectome in major depressive disorder by ketamine therapy. Psychol Med. 2022;52(13):2596–605.10.1017/S0033291720004560 PMC9647551 33267926

55.Loureiro JRA Sahib AK Vasavada M Leaver A Kubicki A Wade B Joshi S Hellemann G Congdon E Woods RP Ketamine’s modulation of cerebro-cerebellar circuitry during response inhibition in major depression NeuroImage-Clin 2021 32 9 10.1016/j.nicl.2021.102792 PMC8476854 34571429 Loureiro JRA, Sahib AK, Vasavada M, Leaver A, Kubicki A, Wade B, Joshi S, Hellemann G, Congdon E, Woods RP, et al. Ketamine’s modulation of cerebro-cerebellar circuitry during response inhibition in major depression. NeuroImage-Clin. 2021;32:9.10.1016/j.nicl.2021.102792 PMC8476854 34571429

56.Pillai RLI Chuan H LaBella A Zhang M Jie Y Trivedi M Weissman M McGrath P Fava M Kurian B Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response J Affect Disord 2019 256 8 16 31158720 PMC6750958 10.1016/j.jad.2019.05.055 Pillai RLI, Chuan H, LaBella A, Zhang M, Jie Y, Trivedi M, Weissman M, McGrath P, Fava M, Kurian B, et al. Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response. J Affect Disord. 2019;256:8–16.10.1016/j.jad.2019.05.055 PMC6750958 31158720

57.Diekamp B Borentain S Fu D-J Murray R Heerlein K Zhang Q Schuele C Mathews M Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials Neuropsychiatr Dis Treat 2021 17 2347 57 34290505 PMC8289440 10.2147/NDT.S314874 Diekamp B, Borentain S, Fu D-J, Murray R, Heerlein K, Zhang Q, Schuele C, Mathews M. Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials. Neuropsychiatr Dis Treat. 2021;17:2347–57.10.2147/NDT.S314874 PMC8289440 34290505

58.Tonhajzerova I Sekaninova N Olexova LB Visnovcova Z Novel Insight into Neuroimmune Regulatory Mechanisms and Biomarkers Linking Major Depression and Vascular Diseases: The Dilemma Continues Int J Mol Sci 2020 21 7 15 10.3390/ijms21072317 PMC7177743 32230840 Tonhajzerova I, Sekaninova N, Olexova LB, Visnovcova Z. Novel Insight into Neuroimmune Regulatory Mechanisms and Biomarkers Linking Major Depression and Vascular Diseases: The Dilemma Continues. Int J Mol Sci. 2020;21(7):15.10.3390/ijms21072317 PMC7177743 32230840

59.Ceruso A Martínez-Cengotitabengoa M Peters-Corbett A Diaz-Gutierrez MJ Martínez-Cengotitabengoa M Alterations of the HPA Axis Observed in Patients with Major Depressive Disorder and Their Relation to Early Life Stress: A Systematic Review Neuropsychobiology 2020 79 6 417 27 32203965 10.1159/000506484 Ceruso A, Martínez-Cengotitabengoa M, Peters-Corbett A, Diaz-Gutierrez MJ, Martínez-Cengotitabengoa M. Alterations of the HPA Axis Observed in Patients with Major Depressive Disorder and Their Relation to Early Life Stress: A Systematic Review. Neuropsychobiology. 2020;79(6):417–27.10.1159/000506484 32203965

60.Ruiz NAL Del Angel DS Brizuela NO Peraza AV Olguín HJ Soto MP Guzmán DC Inflammatory Process and Immune System in Major Depressive Disorder Int J Neuropsychopharmacol 2022 25 1 46 53 34724041 PMC8756095 10.1093/ijnp/pyab072 Ruiz NAL, Del Angel DS, Brizuela NO, Peraza AV, Olguín HJ, Soto MP, Guzmán DC. Inflammatory Process and Immune System in Major Depressive Disorder. Int J Neuropsychopharmacol. 2022;25(1):46–53.10.1093/ijnp/pyab072 PMC8756095 34724041

61.Lynall ME Turner L Bhatti J Cavanagh J de Boer P Mondelli V Jones D Drevets WC Cowen P Harrison NA Peripheral Blood Cell-Stratified Subgroups of Inflamed Depression Biol Psychiatry 2020 88 2 185 96 32000983 10.1016/j.biopsych.2019.11.017 Lynall ME, Turner L, Bhatti J, Cavanagh J, de Boer P, Mondelli V, Jones D, Drevets WC, Cowen P, Harrison NA, et al. Peripheral Blood Cell-Stratified Subgroups of Inflamed Depression. Biol Psychiatry. 2020;88(2):185–96.10.1016/j.biopsych.2019.11.017 32000983

62.Foley EM Parkinson JT Mitchell RE Turner L Khandaker GM Peripheral blood cellular immunophenotype in depression: a systematic review and meta-analysis Mol Psychiatr 2023 28 3 1004 19 10.1038/s41380-022-01919-7 PMC10005954 36577838 Foley EM, Parkinson JT, Mitchell RE, Turner L, Khandaker GM. Peripheral blood cellular immunophenotype in depression: a systematic review and meta-analysis. Mol Psychiatr. 2023;28(3):1004–19.10.1038/s41380-022-01919-7 PMC10005954 36577838

63.Duman RS Sanacora G Krystal JH Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments Neuron 2019 102 1 75 90 30946828 PMC6450409 10.1016/j.neuron.2019.03.013 Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019;102(1):75–90.10.1016/j.neuron.2019.03.013 PMC6450409 30946828

64.Sequeira A Mamdani F Ernst C Vawter MP Bunney WE Lebel V Rehal S Klempan T Gratton A Benkelfat C Global Brain Gene Expression Analysis Links Glutamatergic and GABAergic Alterations to Suicide and Major Depression PLoS ONE 2009 4 8 14 10.1371/journal.pone.0006585 PMC2719799 19668376 Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V, Rehal S, Klempan T, Gratton A, Benkelfat C, et al. Global Brain Gene Expression Analysis Links Glutamatergic and GABAergic Alterations to Suicide and Major Depression. PLoS ONE. 2009;4(8):14.10.1371/journal.pone.0006585 PMC2719799 19668376

65.Duric V Banasr M Stockmeier CA Simen AA Newton SS Overholser JC Jurjus GJ Dieter L Duman RS Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects Int J Neuropsychopharmacol 2013 16 1 69 82 22339950 10.1017/S1461145712000016 PMC3414647 Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC, Jurjus GJ, Dieter L, Duman RS. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int J Neuropsychopharmacol. 2013;16(1):69–82.10.1017/S1461145712000016 PMC3414647 22339950

66.Kang L Xu BY Morozov D Evaluating State Space Discovery by Persistent Cohomology in the Spatial Representation System Front Comput Neurosci 2021 15 16 10.3389/fncom.2021.616748 PMC8060447 33897395 Kang L, Xu BY, Morozov D. Evaluating State Space Discovery by Persistent Cohomology in the Spatial Representation System. Front Comput Neurosci. 2021;15:16.10.3389/fncom.2021.616748 PMC8060447 33897395

67.Yao GQ Pan JJ Zou T Li J Li J He X Zhang FQ Xu Y Structure-function coupling changes in first-episode, treatment-naïve schizophrenia correlate with cell type-specific transcriptional signature BMC Med 2024 22 1 17 10.1186/s12916-024-03714-3 PMC11515592 39443976 Yao GQ, Pan JJ, Zou T, Li J, Li J, He X, Zhang FQ, Xu Y. Structure-function coupling changes in first-episode, treatment-naïve schizophrenia correlate with cell type-specific transcriptional signature. BMC Med. 2024;22(1):17.10.1186/s12916-024-03714-3 PMC11515592 39443976

68.Krishnamurthy P Silberberg G Lansner A Long-range recruitment of Martinotti cells causes surround suppression and promotes saliency in an attractor network model Front Neural Circuits 2015 9 15 10.3389/fncir.2015.00060 PMC4604243 26528143 Krishnamurthy P, Silberberg G, Lansner A. Long-range recruitment of Martinotti cells causes surround suppression and promotes saliency in an attractor network model. Front Neural Circuits. 2015;9:15.10.3389/fncir.2015.00060 PMC4604243 26528143

69.Du Y Li J Wang M Tian Q Pang Y Wen Y Wu D Wang YT Dong Z Genetic inhibition of glutamate allosteric potentiation of GABA < sub>A Rs in mice results in hyperexcitability, leading to neurobehavioral abnormalities MedComm 2023 4 3 e235 37101797 PMC10123808 10.1002/mco2.235 Du Y, Li J, Wang M, Tian Q, Pang Y, Wen Y, Wu D, Wang YT, Dong Z. Genetic inhibition of glutamate allosteric potentiation of GABA < sub>A Rs in mice results in hyperexcitability, leading to neurobehavioral abnormalities. MedComm. 2023;4(3):e235.10.1002/mco2.235 PMC10123808 37101797

70.Chu TP Si XP Xie HZ Ma H Shi YH Yao W Xing D Zhao F Dong FH Gai Q Regional Structural-Functional Connectivity Coupling in Major Depressive Disorder Is Associated With Neurotransmitter and Genetic Profiles Biol Psychiatry 2025 97 3 290 301 39218135 10.1016/j.biopsych.2024.08.022 Chu TP, Si XP, Xie HZ, Ma H, Shi YH, Yao W, Xing D, Zhao F, Dong FH, Gai Q, et al. Regional Structural-Functional Connectivity Coupling in Major Depressive Disorder Is Associated With Neurotransmitter and Genetic Profiles. Biol Psychiatry. 2025;97(3):290–301.10.1016/j.biopsych.2024.08.022 39218135

71.Liu XX Niu JP Liao W Du L Alterations in gray matter volume and associated transcriptomics after electroconvulsive therapy in major depressive disorder Psychol Med 2025 55 8 10.1017/S0033291725000868 PMC12094620 40254982 Liu XX, Niu JP, Liao W, Du L. Alterations in gray matter volume and associated transcriptomics after electroconvulsive therapy in major depressive disorder. Psychol Med. 2025;55:8.10.1017/S0033291725000868 PMC12094620 40254982

72.Tiger M Varnäs K Okubo Y Lundberg J The 5-HT1B receptor - a potential target for antidepressant treatment Psychopharmacology 2018 235 5 1317 34 10.1007/s00213-018-4872-1 29546551 PMC5919989 Tiger M, Varnäs K, Okubo Y, Lundberg J. The 5-HT1B receptor - a potential target for antidepressant treatment. Psychopharmacology. 2018;235(5):1317–34.10.1007/s00213-018-4872-1 PMC5919989 29546551

73.Gärde M Matheson GJ Varnaes K Svenningsson P Hedman-Lagerloef E Lundberg J Farde L Tiger M Altered Serotonin 1B Receptor Binding After Escitalopram for Depression Is Correlated With Treatment Effect Int J Neuropsychopharmacol 2024 27 5 9 10.1093/ijnp/pyae021 PMC11119883 38695786 Gärde M, Matheson GJ, Varnaes K, Svenningsson P, Hedman-Lagerloef E, Lundberg J, Farde L, Tiger M. Altered Serotonin 1B Receptor Binding After Escitalopram for Depression Is Correlated With Treatment Effect. Int J Neuropsychopharmacol. 2024;27(5):9.10.1093/ijnp/pyae021 PMC11119883 38695786

74.Nord M Finnema SJ Halldin C Farde L Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain Int J Neuropsychopharmacol 2013 16 7 1577 86 23351590 10.1017/S1461145712001617 Nord M, Finnema SJ, Halldin C, Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int J Neuropsychopharmacol. 2013;16(7):1577–86.10.1017/S1461145712001617 23351590

75.Atzori M Cuevas-Olguin R Esquivel-Rendon E Garcia-Oscos F Salgado-Delgado RC Saderi N Miranda-Morales M Trevino M Pineda JC Salgado H Locus Ceruleus Norepinephrine Release: A Central Regulator of CNS Spatio-Temporal Activation? Front Synaptic Neurosci 2016 8 25 27616990 PMC4999448 10.3389/fnsyn.2016.00025 Atzori M, Cuevas-Olguin R, Esquivel-Rendon E, Garcia-Oscos F, Salgado-Delgado RC, Saderi N, Miranda-Morales M, Trevino M, Pineda JC, Salgado H. Locus Ceruleus Norepinephrine Release: A Central Regulator of CNS Spatio-Temporal Activation? Front Synaptic Neurosci. 2016;8:25.10.3389/fnsyn.2016.00025 PMC4999448 27616990

76.Chen ST Zhang JQ Wu GW Ouyang X Liu ZN Lv DS Han ZL Xiang YH Tan C Xu C Norepinephrine system dysconnectivity in major depressive disorder: the effect of short term SSRI treatment Eur Neuropsychopharmacol 2025 97 40 50 40543361 10.1016/j.euroneuro.2025.05.010 Chen ST, Zhang JQ, Wu GW, Ouyang X, Liu ZN, Lv DS, Han ZL, Xiang YH, Tan C, Xu C, et al. Norepinephrine system dysconnectivity in major depressive disorder: the effect of short term SSRI treatment. Eur Neuropsychopharmacol. 2025;97:40–50.10.1016/j.euroneuro.2025.05.010 40543361

Come citare questo studio

Xiang Liu, Yuanzhi He, Lifeng Li, Zhanxiang Hu, Haijun Li, Lihao Wu, Liping Zhang, Zihao Su, HengRui Liu, Guojiang Wu, Dechang Peng. (2026). The molecular and neurochemical basis of altered intrinsic neural timescales in major depressive disorder: a multimodal imaging-transcriptomic investigation of esketamine and sertraline treatment.. BMC psychiatry. DOI: 10.1186/s12888-026-08477-0

Consulta la pubblicazione originale ↗